NASDAQ: VXRTVaxart Inc Stock
$0.59-0.01 (-1.67%)
Updated Dec 2, 2024
VXRT Price
$0.59
Fair Value Price
-$0.25
Market Cap
$134.67M
52 Week Low
$0.52
52 Week High
$1.54
P/E
-1.44x
P/B
1.97x
P/S
11.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.76M
Earnings
-$72.34M
Gross Margin
100%
Operating Margin
-430.07%
Profit Margin
-431.6%
Debt to Equity
1.44
Operating Cash Flow
-$51M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VXRT Overview
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VXRT's potential to beat the market
- VXRT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VXRT
RankedUnranked of 343
RankedUnranked of 343
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.05 | A | |
| $7.56 | A | |
| $3.20 | A |
Be the first to know about important VXRT news, forecast changes, insider trades & much more!
VXRT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VXRT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VXRT ($0.59) is overvalued by 341% relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VXRT ($0.59) is not significantly undervalued (341%) relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VXRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VXRT due diligence checks available for Premium users.
Valuation
VXRT fair value
Fair Value of VXRT stock based on Discounted Cash Flow (DCF)
Price
$0.59
Fair Value
-$0.25
Undervalued by
340.18%
VXRT ($0.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VXRT ($0.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VXRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VXRT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.44x
Industry
-106.56x
Market
28.28x
VXRT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.97x
Industry
5.64x
VXRT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VXRT's financial health
Profit margin
Revenue
$4.9M
Net Income
-$14.1M
Profit Margin
-285.4%
VXRT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VXRT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$166.7M
Liabilities
$98.2M
Debt to equity
1.44
VXRT's short-term liabilities ($80.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VXRT's short-term assets ($66.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VXRT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VXRT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
-$17.0M
Financing
-$10.0k
VXRT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VXRT vs Biotech Stocks
Vaxart Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.